![India on Track for Dengue Vaccine by 2026 India on Track for Dengue Vaccine by 2026](https://i0.wp.com/images.medindia.net/health-images/1200_1000/cyd-tdv-dengvaxia-vaccine.jpg?resize=750%2C625&ssl=1)
India could see a dengue vaccine (1✔ ✔Trusted Source
About a Dengue Vaccine
) by 2026, according to K Anand Kumar, Managing Director of Indian Immunologicals (IIL). This announcement comes as multiple companies race to develop India’s first vaccine for the mosquito-borne disease, which claimed 485 lives last year.
Dengue Crisis in India
Dengue has become a significant public health issue in India, with 289,235 cases reported last year. As of April 2024, there were 19,447 dengue cases and 19 deaths, with nearly 300,000 cases occurring annually.
![twitter](https://i0.wp.com/images.medindia.net/icons/news/social/twitter.png?fit=750%2C43&ssl=1)
![facebook](https://i0.wp.com/images.medindia.net/icons/news/social/facebook.png?fit=750%2C43&ssl=1)
![linkedin](https://i0.wp.com/images.medindia.net/icons/news/social/linkedin.png?fit=750%2C43&ssl=1)
![pinterest](https://i0.wp.com/images.medindia.net/icons/news/social/pinterest.png?fit=750%2C43&ssl=1)
Kumar informed Business Standard that IIL has completed Phase 1 clinical trials and plans to apply for Phase 2 approvals soon. If all goes as planned, the vaccine could be available commercially by 2026-27. Phase 1 trials assess safety, while Phases 2 and 3 evaluate efficacy. IIL’s Phase 1 trials have been successful with no adverse effects reported.
Japanese pharmaceutical company Takeda has also launched local clinical trials in India. A Takeda India spokesperson confirmed receiving a no-objection certificate (NoC) for these trials and is working with Indian health authorities for further approvals. Takeda’s Qdenga, a tetravalent dengue vaccine, is already available in Europe, Indonesia, and Thailand and is planned for India once regulatory approvals are granted.
Takeda has partnered with Hyderabad’s Biological E (BE) to produce up to 50 million doses annually, with a goal to reach 100 million doses per year within a decade. This partnership aims to support National Immunization Programs in endemic countries by 2030. The vaccine’s multi-dose vials will offer cost and logistical benefits for large-scale immunization efforts.
Takeda’s global trials have demonstrated around 84% efficacy against severe dengue, regardless of prior exposure. Alongside Takeda and IIL, the Serum Institute of India and Panacea Biotec are also developing dengue vaccines.
Reference:
- About a Dengue Vaccine – (https://www.cdc.gov/dengue/vaccine/index.html)
Source-Medindia